MORE', SONIA
 Distribuzione geografica
Continente #
NA - Nord America 1.029
AS - Asia 626
EU - Europa 497
SA - Sud America 264
AF - Africa 56
OC - Oceania 1
Totale 2.473
Nazione #
US - Stati Uniti d'America 1.000
BR - Brasile 223
IT - Italia 178
SG - Singapore 167
CN - Cina 149
HK - Hong Kong 130
VN - Vietnam 108
RU - Federazione Russa 84
DE - Germania 67
CI - Costa d'Avorio 35
FI - Finlandia 29
FR - Francia 25
GB - Regno Unito 22
AR - Argentina 21
IE - Irlanda 20
IN - India 20
AT - Austria 18
NL - Olanda 17
MX - Messico 15
CA - Canada 12
ID - Indonesia 9
BD - Bangladesh 8
MA - Marocco 8
SE - Svezia 8
JP - Giappone 7
AE - Emirati Arabi Uniti 6
EC - Ecuador 6
UA - Ucraina 6
PL - Polonia 5
TR - Turchia 5
ZA - Sudafrica 5
PE - Perù 4
SN - Senegal 4
CO - Colombia 3
DK - Danimarca 3
ES - Italia 3
KR - Corea 3
PY - Paraguay 3
UZ - Uzbekistan 3
VE - Venezuela 3
BE - Belgio 2
HN - Honduras 2
HU - Ungheria 2
RO - Romania 2
TW - Taiwan 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
DZ - Algeria 1
GI - Gibilterra 1
IQ - Iraq 1
IS - Islanda 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
PH - Filippine 1
PK - Pakistan 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
Totale 2.473
Città #
Dallas 372
Ashburn 184
Hong Kong 129
Singapore 103
Boardman 49
Ho Chi Minh City 46
Munich 36
Abidjan 35
Beijing 31
Los Angeles 27
São Paulo 24
Hefei 23
The Dalles 23
Chandler 22
New York 21
Dublin 20
Hanoi 19
Chicago 16
Moscow 16
Rome 16
Turku 15
Nuremberg 14
Helsinki 13
Milan 13
Buffalo 12
Denver 10
Frankfurt am Main 10
Guangzhou 10
Ancona 9
Council Bluffs 9
Santa Clara 9
Brooklyn 8
Amsterdam 7
Bari 7
Bologna 7
Da Nang 7
Mexico City 7
Xi'an 7
Lawrence 6
Princeton 6
Shenzhen 6
Turin 6
Biên Hòa 5
Chennai 5
Fairfield 5
Falconara Marittima 5
Jiujiang 5
Montreal 5
North Charleston 5
Orem 5
Phoenix 5
Porto Alegre 5
Redmond 5
Rio de Janeiro 5
Salt Lake City 5
Warsaw 5
Boston 4
Camden 4
Curitiba 4
Dakar 4
Haiphong 4
Houston 4
Johannesburg 4
London 4
Mumbai 4
Osimo 4
Pescara 4
Ribeirão Preto 4
Santo André 4
Tokyo 4
Vienna 4
Washington 4
Yiwu 4
Corridonia 3
Florence 3
Guarulhos 3
Holstebro 3
Lima 3
Magnesia ad Sipylum 3
Manchester 3
Montesilvano Marina 3
New Delhi 3
Ninh Bình 3
Poplar 3
Ribeirão das Neves 3
San Francisco 3
Seattle 3
Seoul 3
Stockholm 3
Tashkent 3
Tlalpan 3
Toronto 3
Altamura 2
Araruama 2
Araçatuba 2
Atlanta 2
Aversa 2
Belo Horizonte 2
Berazategui 2
Bogotá 2
Totale 1.621
Nome #
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial 194
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 106
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 98
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 93
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 89
Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre 86
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 85
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 84
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 84
Developments in consolidation and maintenance strategies in post-remission multiple myeloma 82
Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia 79
Editorial: Reviews in hematologic malignancies 76
Current Main Topics in Multiple Myeloma 70
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy 69
AL amyloidosis: an overview on diagnosis, staging system, and treatment 68
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 66
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study 65
A rare case of solitary plasmacytoma mimicking submucosal lesion of ascending colon: a case report and literature review 65
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group 64
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 64
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety 63
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 61
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights 60
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 59
Plasma cell leukemia: first diagnostic approach in the laboratory|Leucemia plasmacellulare: primo inquadramento diagnostico in laboratorio 57
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 57
Long-Term Survival with Multiple Myeloma: An Italian Experience 56
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 55
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences 55
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 53
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 51
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 47
Monoclonal antibodies: Leading actors in the relapsed/refractory multiple myeloma treatment 47
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 44
Novel Experimental Drugs for Treatment of Multiple Myeloma 40
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments 40
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience 26
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients 25
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy 9
Totale 2.592
Categoria #
all - tutte 10.199
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.199


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202232 0 0 0 0 0 0 10 0 6 2 7 7
2022/202372 8 7 8 3 5 3 0 3 16 0 13 6
2023/2024190 22 3 7 5 22 6 3 6 8 8 26 74
2024/2025783 65 36 20 11 16 77 86 29 162 87 89 105
2025/20261.515 215 230 461 300 267 42 0 0 0 0 0 0
Totale 2.592